References
- Deverka P, Vernon J, McLeod H. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol.50, 423–437 (2010).
- Gold H, Hall M, Blinder V et al. Cost–effectiveness of pharmacogenomics testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer115(17), 3858–3867 (2009).
- Deverka P. Pharmacogenomics, evidence, and the role of payers. Pub. Health Gen.12, 149–157 (2009).
- Piccart-Gebhart M, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in Her-2 positive breast cancer. N. Engl. J. Med.352, 1659–1672 (2005).
- Romond E, Perez E, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
- Frueh F, Amur S, Mummaneni M et al.Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration. Prevalence of related drug use. Pharmacotherapy28(8), 992–998 (2008).
- Cohen J, Manzolillo K, Wilson A. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics (2011) (In Press).
- Giaccone G. The role of gefitinib in lung cancer treatment. Clin. Cancer Res.10(12), 4233S–4237S (2004).
- Khoury M, Berg A, Coates R et al. The evidence dilemma in genomic medicine. Health Aff.27(6), 1600–1611 (2008).
- Meckley L, Neumann P. Personalized medicine. Factors influencing reimbursement. Health Pol.94, 91–100 (2010).
- Phillips K. The intersection of biotechnology and pharmacogenomics. Health policy implications. Health Aff.25, 1271–1280 (2006).
- Mallal S, Phillips E, Giampiero C et al.HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358, 568–579 (2008).
- Paci D, Ibarreta D. Economic and cost–effectiveness considerations for pharmacogenetics tests. An integral part of translational research and innovation uptake in personalized medicine. Curr. Pharmacogen. Pers. Med.7, 284–296 (2009).
- Epstein R, Russell Teagarden J. Comparative effectiveness research and personalized medicine. Pharmacoeconomics28(10), 905–913 (2010).
- Tanisha C, Reginald D, Williams A et al. Medicare’s coverage of colorectal cancer drugs. A case study in evidence development and policy. Health. Aff.25(5), 1231–1239 (2009).
- Hamburg M, Collins F. The path to personalized medicine. N. Engl. J. Med.363, 301–304 (2010).
Websites
- Abernethy AP, Coeytaux RR, Carson K et al. Report on the evidence regarding off-label indications for targeted therapies used in cancer treatment. (2010). www.cms.gov/determinationprocess/downloads/id71TA.pdf
- European Medicines Agency www.ema.europa.edu
- National Institution for Health and Clinical Excellence www.nice.org.uk
- Reuters. FDA proposes targeted drug testing guidelines. 12 July 2011 www.reuters.com/article/2011/07/12/us-fda-diagnostics-guidelines-idUSTRE76B60A20110712
- Chustecka Z. Crizotinib in ALK-NSCLC; response rate “unprecedented.” Medscape Medical News 7 June (2010) www.medscape.com/viewarticle/723075